EVA is registered trademark of Stern Stewart.
Economic value added or economic profit is the difference between revenues and costs,where costs include not only expenses, but also cost of capital.
Paying user area
Try for free
Regeneron Pharmaceuticals Inc. pages available for free this week:
- Analysis of Profitability Ratios
- Analysis of Solvency Ratios
- Enterprise Value (EV)
- Present Value of Free Cash Flow to Equity (FCFE)
- Operating Profit Margin since 2005
- Current Ratio since 2005
- Total Asset Turnover since 2005
- Price to Operating Profit (P/OP) since 2005
- Price to Book Value (P/BV) since 2005
- Analysis of Revenues
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Regeneron Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Economic Profit
| 12 months ended: | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | |
|---|---|---|---|---|---|---|
| Net operating profit after taxes (NOPAT)1 | ||||||
| Cost of capital2 | ||||||
| Invested capital3 | ||||||
| Economic profit4 | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 NOPAT. See details »
2 Cost of capital. See details »
3 Invested capital. See details »
4 2025 Calculation
Economic profit = NOPAT – Cost of capital × Invested capital
= – × =
The period under review demonstrates fluctuating financial performance as measured by economic profit. Net operating profit after taxes (NOPAT) experienced a significant decline from 2021 to 2022, followed by relative stabilization and modest increases in subsequent years. Invested capital generally increased throughout the period, while the cost of capital remained relatively stable. Consequently, economic profit mirrored the trend in NOPAT, exhibiting a substantial decrease initially, then a period of recovery, but not returning to the levels observed in 2021.
- NOPAT Trend
- NOPAT decreased considerably from US$7,819,887 thousand in 2021 to US$3,547,649 thousand in 2022, representing a decline of over 50%. A further decrease was observed in 2023, reaching US$2,823,336 thousand. However, NOPAT showed improvement in 2024, increasing to US$3,374,924 thousand, and remained relatively stable in 2025 at US$3,147,470 thousand. This suggests potential stabilization after the initial downturn, but not a full recovery to prior levels.
- Cost of Capital
- The cost of capital remained consistently high throughout the period, fluctuating between 9.65% and 9.79%. The minimal variation suggests a stable capital structure and financing environment. The slight decrease in 2025 to 9.73% is not substantial enough to indicate a significant shift in the company’s risk profile or funding costs.
- Invested Capital Trend
- Invested capital increased from US$10,786,500 thousand in 2021 to US$12,287,700 thousand in 2022. A slight decrease was noted in 2023 to US$11,998,500 thousand, followed by further increases in 2024 (US$12,653,600 thousand) and 2025 (US$13,198,700 thousand). This indicates a continued investment in the business, despite the fluctuations in NOPAT.
- Economic Profit Trend
- Economic profit followed the pattern of NOPAT, declining sharply from US$6,779,389 thousand in 2021 to US$2,347,413 thousand in 2022. It continued to decrease in 2023 to US$1,648,198 thousand before showing improvement in 2024, reaching US$2,142,813 thousand. The economic profit in 2025 was US$1,862,888 thousand. The consistent positive economic profit values indicate that the company is generating returns above its cost of capital, although the magnitude of those returns has varied considerably.
The observed trends suggest a period of adjustment following 2021. While the company continues to generate economic profit, the declining trend in NOPAT and subsequent impact on economic profit warrants further investigation to understand the underlying drivers and potential mitigation strategies.
Net Operating Profit after Taxes (NOPAT)
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 Elimination of deferred tax expense. See details »
2 Addition of increase (decrease) in deferred revenue.
3 Addition of increase (decrease) in equity equivalents to net income.
4 2025 Calculation
Interest expense on capitalized operating leases = Operating lease liability × Discount rate
= × =
5 2025 Calculation
Tax benefit of interest expense = Adjusted interest expense × Statutory income tax rate
= × 21.00% =
6 Addition of after taxes interest expense to net income.
7 2025 Calculation
Tax expense (benefit) of investment income = Investment income, before tax × Statutory income tax rate
= × 21.00% =
8 Elimination of after taxes investment income.
The financial performance, as indicated by Net Income and Net Operating Profit After Taxes (NOPAT), demonstrates considerable fluctuation over the five-year period. A significant decline in both metrics is observed between 2021 and 2023, followed by a partial recovery in subsequent years.
- NOPAT Trend
- NOPAT experienced a substantial decrease from US$7,819,887 thousand in 2021 to US$2,823,336 thousand in 2023, representing a decline of approximately 64%. This suggests a weakening in core operational profitability. A subsequent increase to US$3,374,924 thousand in 2024 indicates some recovery, but NOPAT decreased again in 2025 to US$3,147,470 thousand, suggesting the recovery may not be sustained.
- Relationship between Net Income and NOPAT
- While both Net Income and NOPAT follow a similar pattern of decline and partial recovery, NOPAT consistently represents a larger value than Net Income. This difference could be attributed to factors not reflected in net income, such as non-operating expenses or gains, or differences in accounting treatment. The gap between the two metrics appears relatively stable throughout the period.
The observed volatility in NOPAT warrants further investigation to determine the underlying drivers. Potential areas of inquiry include changes in revenue, cost of goods sold, operating expenses, and tax rates. The decrease in 2025, following the 2024 increase, suggests potential challenges in maintaining operational efficiency or market position.
- Overall Performance
- The period under review demonstrates a period of instability. While the company shows some ability to recover from the low point in 2023, the performance in 2025 indicates that the recovery may be limited. Continued monitoring of NOPAT and its contributing factors is recommended.
Cash Operating Taxes
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
The relationship between income tax expense and cash operating taxes demonstrates notable fluctuations over the five-year period. Cash operating taxes generally exceed income tax expense, suggesting timing differences between reported accounting income and actual cash outflows for taxes.
- Overall Trend - Cash Operating Taxes
- Cash operating taxes exhibit a decreasing trend from 2021 to 2023, followed by a slight increase in 2024 and a more substantial rise in 2025. The value decreased from US$1,400,760 thousand in 2021 to US$995,682 thousand in 2023, representing a 28.9% decline. A modest increase to US$989,515 thousand occurred in 2024, before a significant jump to US$1,372,884 thousand in 2025.
- Overall Trend - Income Tax Expense
- Income tax expense shows a significant decrease from 2021 to 2022, followed by continued declines through 2023, a slight increase in 2024, and a further increase in 2025. The value fell from US$1,250,500 thousand in 2021 to US$245,700 thousand in 2023, a decrease of 80.3%. An increase to US$367,300 thousand was observed in 2024, and a further increase to US$725,800 thousand in 2025.
- Relationship Between Tax Items
- The difference between cash operating taxes and income tax expense varied considerably. In 2021, cash operating taxes exceeded income tax expense by US$150,260 thousand. This difference narrowed in 2022 to US$725,998 thousand. By 2023, cash operating taxes exceeded income tax expense by US$750,000 thousand. The difference decreased to US$622,115 thousand in 2024, and then increased to US$647,084 thousand in 2025. This suggests that deferred tax assets or liabilities are playing a significant role in the company’s tax position.
The substantial fluctuations in both income tax expense and cash operating taxes warrant further investigation to understand the underlying drivers, such as changes in tax laws, the utilization of tax credits, or alterations in the company’s accounting practices related to deferred taxes. The increasing trend in both measures in 2025 suggests a potential increase in future tax liabilities.
Invested Capital
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 Addition of capitalized operating leases.
2 Elimination of deferred taxes from assets and liabilities. See details »
3 Addition of deferred revenue.
4 Addition of equity equivalents to stockholders’ equity.
5 Removal of accumulated other comprehensive income.
6 Subtraction of construction in progress.
7 Subtraction of marketable securities.
The invested capital of the organization demonstrates a generally increasing trend over the five-year period, although with some fluctuation. Total reported debt & leases and stockholders’ equity both contribute to this figure, and their individual movements influence the overall invested capital.
- Invested Capital Trend
- Invested capital increased from US$10,786,500 thousand in 2021 to US$12,287,700 thousand in 2022, representing a substantial rise. A decrease was then observed in 2023, with invested capital falling to US$11,998,500 thousand. Subsequent years show renewed growth, reaching US$12,653,600 thousand in 2024 and US$13,198,700 thousand in 2025. This suggests periods of capital investment followed by potential adjustments or reallocations.
- Debt & Leases
- Total reported debt & leases exhibits a consistent, albeit moderate, upward trend throughout the period. Starting at US$2,767,900 thousand in 2021, it increases to US$2,972,700 thousand in 2025. The increases are relatively steady year-over-year, indicating a consistent reliance on debt financing.
- Stockholders’ Equity
- Stockholders’ equity demonstrates a strong and consistent upward trend. It increased significantly from US$18,768,800 thousand in 2021 to US$31,256,900 thousand in 2025. This growth suggests successful earnings retention and/or new equity issuance, contributing significantly to the overall increase in invested capital.
- Relationship between Components
- While both debt & leases and stockholders’ equity contribute to invested capital, stockholders’ equity represents the larger portion and drives the majority of the overall trend. The relatively smaller increases in debt & leases are overshadowed by the substantial growth in equity. The dip in invested capital in 2023 appears to be influenced by a combination of factors, including a slight decrease in equity growth and the impact of debt levels.
In summary, the organization’s invested capital has generally increased over the observed period, primarily driven by growth in stockholders’ equity. Debt & leases have also increased, but to a lesser extent. The fluctuation in invested capital in 2023 warrants further investigation to understand the underlying causes.
Cost of Capital
Regeneron Pharmaceuticals Inc., cost of capital calculations
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | ÷ | = | × | = | |||||||||
| Long-term debt and finance lease liabilities3 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Operating lease liability4 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Total: | |||||||||||||
Based on: 10-K (reporting date: 2025-12-31).
1 US$ in thousands
2 Equity. See details »
3 Long-term debt and finance lease liabilities. See details »
4 Operating lease liability. See details »
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | ÷ | = | × | = | |||||||||
| Long-term debt and finance lease liabilities3 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Operating lease liability4 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Total: | |||||||||||||
Based on: 10-K (reporting date: 2024-12-31).
1 US$ in thousands
2 Equity. See details »
3 Long-term debt and finance lease liabilities. See details »
4 Operating lease liability. See details »
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | ÷ | = | × | = | |||||||||
| Long-term debt and finance lease liabilities3 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Operating lease liability4 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Total: | |||||||||||||
Based on: 10-K (reporting date: 2023-12-31).
1 US$ in thousands
2 Equity. See details »
3 Long-term debt and finance lease liabilities. See details »
4 Operating lease liability. See details »
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | ÷ | = | × | = | |||||||||
| Long-term debt and finance lease liabilities3 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Operating lease liability4 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Total: | |||||||||||||
Based on: 10-K (reporting date: 2022-12-31).
1 US$ in thousands
2 Equity. See details »
3 Long-term debt and finance lease liabilities. See details »
4 Operating lease liability. See details »
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | ÷ | = | × | = | |||||||||
| Long-term debt and finance lease liabilities3 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Operating lease liability4 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Total: | |||||||||||||
Based on: 10-K (reporting date: 2021-12-31).
1 US$ in thousands
2 Equity. See details »
3 Long-term debt and finance lease liabilities. See details »
4 Operating lease liability. See details »
Economic Spread Ratio
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Economic profit1 | ||||||
| Invested capital2 | ||||||
| Performance Ratio | ||||||
| Economic spread ratio3 | ||||||
| Benchmarks | ||||||
| Economic Spread Ratio, Competitors4 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 Economic profit. See details »
2 Invested capital. See details »
3 2025 Calculation
Economic spread ratio = 100 × Economic profit ÷ Invested capital
= 100 × ÷ =
4 Click competitor name to see calculations.
The economic spread ratio demonstrates a significant decline from 2021 to 2023, followed by a modest recovery in subsequent years. Economic profit fluctuates over the period, while invested capital consistently increases. This analysis details these trends and their implications.
- Economic Spread Ratio
- The economic spread ratio decreased substantially from 62.85% in 2021 to 19.10% in 2022, representing a considerable reduction in the return generated on invested capital relative to the cost of that capital. A further decline to 13.74% occurred in 2023, indicating continued pressure on profitability relative to invested capital. The ratio experienced a partial recovery in 2024, rising to 16.93%, and remained relatively stable at 14.11% in 2025. Despite the recovery, the ratio did not return to the levels observed in 2021.
- Economic Profit
- Economic profit peaked at US$6,779,389 thousand in 2021. Subsequent years saw a marked decrease, with economic profit falling to US$2,347,413 thousand in 2022 and further to US$1,648,198 thousand in 2023. A moderate increase was observed in 2024, reaching US$2,142,813 thousand, followed by a slight decrease to US$1,862,888 thousand in 2025. The fluctuations in economic profit directly influence the economic spread ratio.
- Invested Capital
- Invested capital exhibited a consistent upward trend throughout the analyzed period. It increased from US$10,786,500 thousand in 2021 to US$13,198,700 thousand in 2025. This continuous growth in invested capital, coupled with the fluctuations in economic profit, contributes to the observed changes in the economic spread ratio. The increasing capital base suggests ongoing investment in the business, but the ratio indicates that these investments have not consistently translated into proportionally higher returns.
The combination of decreasing economic profit in the initial years and increasing invested capital likely drove the significant decline in the economic spread ratio. While economic profit showed some improvement in 2024, it was insufficient to fully offset the continued growth in invested capital and restore the ratio to its 2021 level. The stabilization of the ratio in 2025 suggests a potential leveling off of the negative trend, but continued monitoring is warranted.
Economic Profit Margin
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Economic profit1 | ||||||
| Revenues | ||||||
| Add: Increase (decrease) in deferred revenue | ||||||
| Adjusted revenues | ||||||
| Performance Ratio | ||||||
| Economic profit margin2 | ||||||
| Benchmarks | ||||||
| Economic Profit Margin, Competitors3 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 Economic profit. See details »
2 2025 Calculation
Economic profit margin = 100 × Economic profit ÷ Adjusted revenues
= 100 × ÷ =
3 Click competitor name to see calculations.
The economic profit margin demonstrates a declining trend over the observed period, followed by a period of stabilization. Economic profit itself fluctuates, but the margin reveals the efficiency with which revenue is translated into economic profit.
- Economic Profit Margin Trend
- In 2021, the economic profit margin stood at 42.50%. A substantial decrease was observed in 2022, falling to 19.23%. This decline continued into 2023, reaching a low of 12.53%. A modest recovery occurred in 2024, with the margin increasing to 14.85%. The margin experienced a slight decrease in 2025, settling at 13.04%.
The most significant shift occurred between 2021 and 2023, indicating a reduced ability to generate economic profit from each dollar of revenue during that timeframe. The subsequent stabilization between 2024 and 2025 suggests that the factors contributing to the earlier decline may have been addressed or reached a new equilibrium.
- Relationship to Economic Profit
- While economic profit decreased from 2021 to 2023, the decline in the economic profit margin was more pronounced. This suggests that revenue also experienced a decline, but not at the same rate as the reduction in economic profit. The increase in economic profit from 2023 to 2024 was accompanied by a corresponding increase in the economic profit margin, indicating a more efficient use of revenue to generate profit.
The economic profit margin’s recent performance suggests a period of adjustment and potential stabilization. Continued monitoring is recommended to determine if the margin can return to levels observed in 2021 or if the current range represents a new normal.